LTZ Therapeutics, a Palo Alto, CA and Shenzhen, China-based biotech firm, raised $17M in Pre-Collection A funding.
The spherical was led by K2 Enterprise Companions, with participation from Qiming Enterprise Companions and Tigermed.
The corporate intends to make use of the funds to develop its three-pronged platform, set up its preliminary pipeline and to additional construct the operations group.
Co-founded by seasoned drug builders Robert Li Ph.D, Martin Treder Ph.D and Jianhui Zhou Ph.D., LTZ Therapeutics is an immunotherapy-focused biotech firm pursuing the event of therapies to enhance medical outcomes in sufferers with most cancers and different ailments with an unmet medical want. It’s devoted to growing immunotherapies able to overcoming resistance and boosting anti-tumor immunity primarily based on reverse translational science and rising biology of tumor microenvironment.